Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by Froggy101on Jan 17, 2023 10:53am
147 Views
Post# 35227879

The unknown

The unknown This as been frustrating for a long time , it's all been promised speech of great things to come without the shareholder seeing nothing and knowing nothing on what's really going on . Where's the transparency? Why can't we get some awnser? Can we get some details on the default and repayment / dates etc? The excuse given at the road show that we simply ran out of money and this deal was the only option makes no sense to me if the technology works. We need clarity. Or the technology is dead and useless. At this point with the share price of .04 tell me it's not working and I'll lick my wound and carry on . But why still pushing on xb3  for hunter's syndrome if they know it doesn't work ? Think about it !something fishy here , I'm putting my tin hat here and paying attention to what JD as to say . 
<< Previous
Bullboard Posts
Next >>